151 related articles for article (PubMed ID: 21673434)
1. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.
Pasello M; Manara MC; Michelacci F; Fanelli M; Hattinger CM; Nicoletti G; Landuzzi L; Lollini PL; Caccuri A; Picci P; Scotlandi K; Serra M
Anal Cell Pathol (Amst); 2011; 34(3):131-45. PubMed ID: 21673434
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
3. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
[TBL] [Abstract][Full Text] [Related]
5. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
7. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
[TBL] [Abstract][Full Text] [Related]
8. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
Filomeni G; Turella P; Dupuis ML; Forini O; Ciriolo MR; Cianfriglia M; Pezzola S; Federici G; Caccuri AM
Mol Cancer Ther; 2008 Feb; 7(2):371-9. PubMed ID: 18281520
[TBL] [Abstract][Full Text] [Related]
9. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells.
Turella P; Filomeni G; Dupuis ML; Ciriolo MR; Molinari A; De Maria F; Tombesi M; Cianfriglia M; Federici G; Ricci G; Caccuri AM
J Biol Chem; 2006 Aug; 281(33):23725-32. PubMed ID: 16769721
[TBL] [Abstract][Full Text] [Related]
10. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
11. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
Scotlandi K; Remondini D; Castellani G; Manara MC; Nardi F; Cantiani L; Francesconi M; Mercuri M; Caccuri AM; Serra M; Knuutila S; Picci P
J Clin Oncol; 2009 May; 27(13):2209-16. PubMed ID: 19307502
[TBL] [Abstract][Full Text] [Related]
12. [Soft tissue sarcoma: postoperative chemotherapy].
Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.
Federici L; Lo Sterzo C; Pezzola S; Di Matteo A; Scaloni F; Federici G; Caccuri AM
Cancer Res; 2009 Oct; 69(20):8025-34. PubMed ID: 19808963
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
Liu Q; Liu Z; Hua W; Gou S
J Med Chem; 2021 Feb; 64(3):1701-1712. PubMed ID: 33529017
[TBL] [Abstract][Full Text] [Related]
15. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.
Sau A; Filomeni G; Pezzola S; D'Aguanno S; Tregno FP; Urbani A; Serra M; Pasello M; Picci P; Federici G; Caccuri AM
Mol Biosyst; 2012 Apr; 8(4):994-1006. PubMed ID: 22068640
[TBL] [Abstract][Full Text] [Related]
16. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of advanced sarcomas of bone and soft tissue.
Antman KH
Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
[TBL] [Abstract][Full Text] [Related]
18. 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs.
Ricci G; De Maria F; Antonini G; Turella P; Bullo A; Stella L; Filomeni G; Federici G; Caccuri AM
J Biol Chem; 2005 Jul; 280(28):26397-405. PubMed ID: 15888444
[TBL] [Abstract][Full Text] [Related]
19. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
Hussein D; Holt SV; Brookes KE; Klymenko T; Adamski JK; Hogg A; Estlin EJ; Ward T; Dive C; Makin GW
Br J Cancer; 2009 Jul; 101(1):55-63. PubMed ID: 19491903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
